Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

S'inscrire

CLSD Clearside Biomedical Inc

0,949

0,0989 (11,63%)

Avant marché

Dernière mise à jour : 13:45:34

Retardé de 15 minutes

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Clearside Biomedical (NASDAQ:CLSD)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025

Plus de graphiques de la Bourse Clearside Biomedical

Clearside Biomedical (NASDAQ:CLSD)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025

Plus de graphiques de la Bourse Clearside Biomedical

Actualités Clearside Biomedical Inc

Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD
Jeudi 6 Mars 2025 ( il y a 56 minutes) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Lundi 24 Février 2025 ( il y a 1 semaine) • Edgar (US Regulatory)

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Vendredi 21 Février 2025 ( il y a 2 semaines) • Edgar (US Regulatory)

Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema
Jeudi 20 Février 2025 ( il y a 2 semaines) • GlobeNewswire Inc.

Form 8-K - Current report
Jeudi 13 Février 2025 ( il y a 3 semaines) • Edgar (US Regulatory)

Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting
Lundi 10 Février 2025 ( il y a 3 semaines) • GlobeNewswire Inc.

Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference
Mardi 4 Février 2025 ( il y a 1 mois) • GlobeNewswire Inc.

Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program
Mardi 28 Janvier 2025 ( il y a 1 mois) • GlobeNewswire Inc.

Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore
Mercredi 22 Janvier 2025 ( il y a 1 mois) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Vendredi 10 Janvier 2025 ( il y a 2 mois) • Edgar (US Regulatory)

Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye
Jeudi 19 Décembre 2024 ( il y a 3 mois) • GlobeNewswire Inc.

Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States
Lundi 25 Novembre 2024 ( il y a 3 mois) • GlobeNewswire Inc.

Plus d'articles sur Clearside Biomedical Inc

Lvmh Moet Hennessy Louis...

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales